News

Soluna Holdings, Inc. filed a Form 8-K on November 9, 2026, disclosing via Regulation FD that it will release its third quarter 2026 financial results on November 16, 2026, and host a conference call and webcast at 5:00 PM ET that day.

FACT II Acquisition Corp. filed a current report on November 9, 2026, disclosing plans to enter into non-redemption agreements with unaffiliated investors ahead of an extraordinary general meeting scheduled for November 17, 2026, to vote on extending the company's business combination deadline.

Immunovant, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $250.470 million for the six months ended September 30, 2026, with cash and cash equivalents of $722.274 million as of that date.

Cullinan Therapeutics, Inc. filed a current report on Form 8-K on November 9, 2026, disclosing interim clinical data from an ongoing Phase 1b/2a trial of velinotamig in patients with active, refractory, moderate-to-severe systemic lupus erythematosus, as presented at the American College of Rheumatology Convergence …

Cadeler plc filed a Form 6-K with the U.S. Securities and Exchange Commission on 9 November 2026, announcing the initiation of a compulsory acquisition of shares in Cadeler A/S held by remaining minority shareholders under sections 70 and 72 of the Danish Companies Act.

Silexion Therapeutics Corp filed a Form 8-K on November 9, 2026, announcing a prospective 1-for-24 reverse share split of its ordinary shares, effective after the close of market on November 10, 2026.

Aura Biosciences, Inc. submitted its quarterly report on Form 10-Q covering the period ended September 30, 2026, disclosing operational risks, development status of its sole product candidate bel-sar, and a share count of 104,074,302 shares of common stock outstanding as of November 4, 2026.